Synuclein alpha promoter and enhancer genomic DNA (SNCA promoter/enhancer)

The Synuclein alpha (SNCA) promoter and enhancer genomic DNA regions are the primary regulatory segments of the SNCA gene, which encodes the alpha-synuclein protein. These regions, including distal enhancers and the intron 1 regulatory element, control the rate of SNCA transcription and are highly sensitive to epigenetic modifications such as DNA methylation and histone acetylation (Mittal et al., 2017; Kantor et al., 2018). In Parkinson's disease and related synucleinopathies, genetic variants (e.g., rs356168) or epigenetic dysregulation in these regions lead to the overexpression of alpha-synuclein, promoting its aggregation into toxic Lewy bodies (Soldner et al., 2016; Mittal et al., 2017). Consequently, these genomic regions have emerged as high-priority therapeutic targets for disease-modifying interventions. Current research explores small molecules like beta-2 adrenergic agonists (e.g., salbutamol) that reduce SNCA expression by altering histone marks, as well as gene-editing tools like CRISPR-dCas9 and zinc-finger proteins designed for targeted transcriptional repression (Mittal et al., 2017; Kantor et al., 2018). However, therapeutic development faces challenges in achieving precise downregulation without compromising the protein's essential roles in synaptic vesicle trafficking and neurotransmitter release. Monitoring these targets often involves measuring SNCA mRNA levels or assessing the methylation status of the promoter and intron 1 regions (Iakovenko et al., 2021).

Other names

SNCA regulatory regionsSNCA distal enhancersSNCA intron 1 regulatory elementSNCA-Rep1NACP promoter

Transcriptional downregulation of the SNCA gene through epigenetic modulation (e.g., DNA methylation, histone acetylation) or direct transcriptional repression.